Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-01-15
2008-01-15
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S247000
Reexamination Certificate
active
07319109
ABSTRACT:
The invention relates to a compound of formula (I):wherein all variables are as defined herein and to pharmaceutical compositions, methods of using, and processes for preparing the same.
REFERENCES:
patent: 6187797 (2001-02-01), Pruitt et al.
patent: 6187814 (2001-02-01), Elias et al.
patent: 312867 (1989-04-01), None
patent: 2293360 (1996-03-01), None
patent: 11263775 (1999-09-01), None
patent: WO-98/57951 (1998-12-01), None
patent: WO 00/37077 (2000-06-01), None
patent: WO-00/59902 (2000-10-01), None
patent: WO-00/64876 (2000-11-01), None
patent: WO-01/19778 (2001-03-01), None
patent: WO-01/25210 (2001-04-01), None
patent: WO 03/015771 (2003-02-01), None
Schulman et al. Chemistry & Biology 2004, 11, 639-646.
Bishop-Bailey et al. PNAS 2004, 101(10), 3668-3673.
Caron et al. Endocrinology 2006, 147(9), 4022-4024.
Claudel et al. Arteriosclerosis, Thrombosis, and Vascular Biology 2005, 25, 2020-2030.
BM Forman. et al; Identification of a nuclear receptor that is activated by farnesol metabolites; Cell; 1995; 81; 687-693.
DJ Mangelsdorf, et al.; The RXR heterodimers and orphan receptors; Cell; 1995; 83: 841-850.
DW Russell, et al.; Nuclear Orphan Receptors Control Cholesterol Catabolism; Cell; 1999; 97; 539-542.
Hofmann, AF; The Continuing Importance of Bile Acids in Liver and Intestinal Disease; Arch Intern Med; 1999; 159; 2647-2658.
Maloney, P. et al.; Identification of a Chemical Tool for the Orphan Nuclear Receptor FXR; J Med Chem; 2000; 43/16; 2971-2974.
Neuberger J; Primary Billary Cirrhosis; Lancet: 1997: 350; 875-879.
Sinal, et al.; Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis; Cell; 2000; 102/6; 731-744.
W Seol, et al.; Isolation of proteins that interact specifically with the retinoid X receptor, two novel orphan receptors; Mol Endocrinol; 1995; 9; 72-85.
Boggs Sharon D
Collins Jon L
Hyatt Stephen M
Maloney Patrick R
Anderson Rebecca
Bradney Alice P.
Nolan Jason M
Smith Kline Beecham Corporation
LandOfFree
Farnesoid X receptor agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Farnesoid X receptor agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Farnesoid X receptor agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2815518